79.94 +0.06 (0.08%)
After hours: 7:32PM EDT
|Bid||75.02 x 100|
|Ask||82.98 x 100|
|Day's Range||79.86 - 81.20|
|52 Week Range||72.67 - 94.19|
|PE Ratio (TTM)||24.58|
|Forward Dividend & Yield||2.98 (3.66%)|
|1y Target Est||N/A|
The 30 most obese countries in the world in 2018 represent a huge (pun intended) market opportunity for weight loss drugmakers. Increasingly sedentary lifestyles and a lack of healthy eating habits among large swaths of the global population have resulted in dramatically rising obesity rates in the past few decades, particularly in urban settings. Obesity is […]
Congress introduced the Consolidated Appropriations Act of 2018 on Wednesday, and the bill contains fewer health care provisions than many traders expected. Still, Height Capital Markets analyst Andrea ...
Glaxo (GSK) has a Zacks Rank #2 (Buy). Its shares have outperformed the industry this year so far. Earnings estimates are also on the rise.
Thus, government regulations and market structure changes are expected to continue to increase pricing pressures on drugmakers, including big players such as Teva Pharmaceutical (TEVA), Sanofi (SNY), Novartis (NVS), and Mylan (MYL). In 4Q17, Teva experienced a price erosion of ~13% in its generics business, which was in line with industry expectations. The company recorded a goodwill impairment of ~$11 million related to its US generics business in 4Q17 as it adjusted its assumptions for determining the fair value of the business, which would be used to calculate its cash flow projections.
Roche's (RHHBY) opthalmology drug, Lucentis 0.3 mg prefilled syringe (PFS) is a new method of administering medicine for all forms of diabetic retinopathy.
The company generated this revenue from research and development under a collaboration agreement with Novartis (NVS). In 2018, Akcea Therapeutics is expected to generate revenue of $71.3 million, while its peers Amgen (AMGN), Ionis Pharmaceuticals (IONS), and bluebird bio (BLUE) are expected to generate revenues of $22.5 billion, $582.4 million, and $23.9 million, respectively. In 2017, Akcea Therapeutics incurred research and development expenses of $126.8 million compared to $68.4 million in 2016.
Novartis subsidiary Sandoz Canada will work with cannabis producer Tilray to produce non-smokable medical cannabis products in Canada, becoming the first Big Pharma company to get into medical pot.
The company announced that it had filed the case in the United States District Court for the District of New Jersey for its Korlym (mifepristone) 300 mg tablet patent. On the day, TEVA stock registered a fall of ~3%, and Corcept Therapeutics stock fell ~0.6%. The suit was filed by Corcept after Teva filed an ANDA (Abbreviated New Drug Application) for FDA approval for selling and marketing a generic version of Korlym.
At the end of December 2017, Ionis was the majority shareholder in Akcea with ~68% ownership. Currently, Akcea has commercialization and licensing agreements with Ionis, and this synergy is expected to benefit the company. Akcea has access to Ionis’s antisense and LICA technologies, which allow for precise specificity, favorable dosing properties, and no anticipated drug-to-drug interactions.
In January, GlaxoSmithKline's (GSK.L) new head of pharmaceuticals Luke Miels issued a blunt challenge to his managers: find budget savings of 20 percent. Miels - a long-time protege of AstraZeneca (AZN.L) CEO Pascal Soriot, whose departure sparked a legal spat between the rival drugmakers - is a key lieutenant for Walmsley as she tries to overhaul the core pharma business. The unit has lagged rivals like Novartis (NOVN.S) and Merck & Co (MRK.N) in producing multibillion-dollar blockbusters, so Walmsley has prioritised plans to refocus both its research and marketing efforts in a drive for fewer but bigger new drugs.
In January, GlaxoSmithKline's (GSK.L) new head of pharmaceuticals Luke Miels issued a blunt challenge to his managers: find budget savings of 20 percent. Miels - a long-time protege of AstraZeneca (AZN.L) CEO Pascal Soriot, whose departure sparked a legal spat between the rival drugmakers - is a key lieutenant for Walmsley as she tries to overhaul the core pharma business. The unit has lagged rivals like Novartis (NOVN.S) and Merck & Co (MRK.N) in producing multibillion-dollar blockbusters, so Walmsley has prioritized plans to refocus both its research and marketing efforts in a drive for fewer but bigger new drugs.
U.S. prosecutors said numerous Novartis AG sales representatives will testify they plied doctors with lavish meals, booze and other benefits in exchange for promises to prescribe the Swiss company’s drugs, ...
Let's see if Novartis AG (NVS) stock is a good choice for value-oriented investors right now, or if investors subscribing to this methodology should look elsewhere for top picks.